Telmisartan showed similar 3-year major adverse cardiac event rates compared to other ARBs (4.6% vs 4.7%, P=0.75) in patients with hypertension taking two or more antihypertensive drugs.
Cohort (n=19,247)
Yes
Does telmisartan reduce major adverse cardiac events compared to other ARBs in patients with hypertension taking two or more antihypertensive medications?
In a real-world cohort of hypertensive patients on multiple medications, telmisartan demonstrated similar 3-year cardiovascular outcomes compared to other ARBs.
Absolute Event Rate: 4.6% vs 4.7%
p-value: p=0.75
BACKGROUND: Telmisartan exhibits superior efficacy in controlling 24-h blood pressure (BP) compared with other angiotensin receptor blockers (ARBs). However, data on its cardiovascular effects in patients with hypertension are limited. This study aimed to evaluate the cardiovascular outcomes in patients taking telmisartan compared to those taking other ARBs. METHODS: This multicenter retrospective study used data from the Korea University Medical Center database, built from electronic health records. A total of 19,247 patients taking two or more antihypertensive medications were identified. Patients prescribed telmisartan (telmisartan users) were compared with those prescribed an ARB other than telmisartan (other ARB users). The primary outcome was major adverse cardiac events (MACE), a composite of cardiovascular death, myocardial infarction, stroke, and hospitalizations due to heart failure. The adjusted outcomes were compared using 1:1 propensity score (PS) matching. RESULTS: Overall, 3,437 (17.9%) patients were telmisartan users. These patients were more likely to be younger and male and less likely to have a history of chronic kidney disease, dialysis, or heart failure. In the PS-matched cohort, BP control was similar in both groups; however, telmisartan users exhibited significantly lower visit-to-visit BP variability. The adjusted 3-year MACE rate was similar between telmisartan users (4.6%) and other ARB users (4.7%, log-rank P = 0.75), with comparable safety profiles. CONCLUSIONS: In real-world practice, telmisartan showed cardiovascular outcomes similar to those of other ARBs in patients with hypertension taking two or more antihypertensive drugs.
Yum et al. (2024) conducted a cohort in Hypertension (n=19,247). Telmisartan vs. Other ARBs was evaluated on Major adverse cardiac events (MACE), a composite of cardiovascular death, myocardial infarction, stroke, and hospitalizations due to heart failure (p=0.75). Telmisartan showed similar 3-year major adverse cardiac event rates compared to other ARBs (4.6% vs 4.7%, P=0.75) in patients with hypertension taking two or more antihypertensive drugs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: